Candida dubliniensis at a University Hospital in Saudi Arabia
|
|
- Herbert Walsh
- 6 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, May 2003, p Vol. 41, No /03/$ DOI: /JCM Copyright 2003, American Society for Microbiology. All Rights Reserved. Candida dubliniensis at a University Hospital in Saudi Arabia R. Fotedar* and S. S. A. Al Hedaithy The Medical Mycology Unit, Department of Pathology, College of Medicine, King Khalid University Hospital, Riyadh 11461, Saudi Arabia Received 2 December 2002/Returned for modification 10 January 2003/Accepted 28 January 2003 Candida dubliniensis is a newly described yeast species that is a close phylogenetic relative of C. albicans. Although it has been reported from different parts of the world, no detailed investigation of this species has been done in Saudi Arabia. The purpose of the present study was to identify C. dubliniensis isolates recovered from clinical specimens at a tertiary-care hospital in Riyadh, Saudi Arabia, and to determine the drug susceptibility profiles of those isolates. Over a period of 8 months, 823 germ tube- and chlamydospore-positive yeasts identified as C. albicans and recovered from different clinical specimens were screened for their ability to grow at 45 C on Sabouraud dextrose agar. Isolates which failed to grow at 45 C were presumptively identified as C. dubliniensis. The species identities were further confirmed by the production of pseudohyphae and chlamydospores on Staib agar and their inability to assimilate D-xylose and -methyl-d-glucoside by using the API 20C AUX system. A total of 27 (3.3%) isolates were identified as C. dubliniensis. They were all recovered from 23 human immunodeficiency virus-negative patients. The prevalence of C. dublinensis in bronchoalveolar lavage (33.3%), oral (16.7%), and blood (16.7%) specimens was high. In addition, 33 isolates previously identified as C. albicans and preserved among our stock blood culture isolates were also recruited for the study. Of these, 5 isolates were found to be C. dubliniensis, thus making the total number of isolates identified as this species 32. Antifungal susceptibility testing of the C. dubliniensis isolates showed 100% sensitivity to amphotericin B, 97% sensitivity to each of fluconazole and ketoconazole, and 87.5% sensitivity to itraconazole. However, in contrast to other studies, the majority of the isolates (65.6%) showed high levels of resistance to flucytosine (MIC > 64 g/ml). Further studies are warranted to investigate the cause of this unusually high rate of resistance to flucytosine of the C. dubliniensis isolates in this region. Candida dubliniensis was first described as a novel species in 1995 by Sullivan et al. (31) and has been reported from various geographic locations (29, 30). Although previously associated with oral candidiasis in human immunodeficiency virus (HIV)- infected patients (5, 30, 31), it has more recently been recognized as a cause of superficial and systemic diseases in HIVnegative and HIV-positive patients (3, 4, 6, 10, 15, 23, 27). The close resemblance of C. albicans and C. dubliniensis has hampered the accurate and rapid identification of the latter from clinical specimens. In a recent retrospective study of the isolates in laboratory stock collections (isolates recovered between 1973 and 1994), approximately 2% of the isolates originally identified as C. albicans were found to be C. dubliniensis (19). However, the availability of numerous reliable and rapid tests, such as an inability to grow at 45 C (9, 11, 12, 22, 23), characteristic morphology on cornmeal agar (6, 11, 31), production of abundant pseudohyphae and chlamydospores on Staib agar (2, 28), formation of dark green colonies on CHROMagar Candida medium (5, 6, 29, 30), and carbohydrate assimilation tests (9, 21, 23, 29, 30) with the API 20C AUX and ID 32C systems (biomerieux, Marcy l Etoile, France), have greatly facilitated the differentiation of C. dubliniensis and C. albicans. In addition, the use of molecular techniques has significantly revolutionized investigations of various aspects of this yeast pathogen (8). * Corresponding author. Mailing address: The Medical Mycology Unit, Department of Pathology & Microbiology (32), College of Medicine, King Khalid University Hospital, Box 32, P.O. Box 2925, Riyadh , Saudi Arabia. Phone: Fax: E- mail: rfotedar@ksu.edu.sa. Although C. dubliniensis and C. albicans isolates are both susceptible to azoles, fluconazole resistance has been observed in clinical isolates of C. dubliniensis from AIDS patients with prior exposure to fluconazole (16, 17, 20). In addition, it has been shown that isolates of C. dubliniensis, unlike those of C. albicans, can develop stable resistance to fluconazole upon exposure in vitro (16, 17), suggesting a need to investigate the sensitivities of isolates of this species from various regions. The present study was undertaken to determine the prevalence of C. dubliniensis isolates in different clinical specimens recovered at a tertiary-care hospital in Riyadh, Saudi Arabia. In addition, testing of the in vitro susceptibilities to different antifungal agents was done for all isolates identified as C. dubliniensis. MATERIALS AND METHODS During an 8-month period (between September 2000 and April 2001), we obtained 823 isolates of C. albicans from various clinical specimens of patients attending King Khalid University Hospital, Riyadh, Saudi Arabia. They were identified as C. albicans on the basis of a positive germ tube test result, production of chlamydospores in cornmeal agar, and resistance to cycloheximide when they were grown on cycloheximide (500 g/ml)-containing medium (1). These isolates were reexamined to explore if any of them were actually C. dubliniensis and not C. albicans. In addition, 33 C. albicans isolates from our stock cultures from blood collected from January 1996 to December 2000 were also included in the study, making the total number of isolates examined 856. Identification as C. dubliniensis. All 856 isolates previously identified as C. albicans were screened for their ability to grow on Sabouraud dextrose agar when they were incubated at 45 C for 48 h. Yeasts that did not grow at 45 C were regarded as possible C. dubliniensis isolates (12, 22). They were then retested for germ tube production in human serum after 3 h of incubation at 37 C and were also cultured on cornmeal agar supplemented with 1% (wt/vol) Tween 80 for detection of production of hyphae and chlamydospores. The isolates were fur- 1907
2 1908 FOTEDAR AND AL HEDAITHY J. CLIN. MICROBIOL. ther subcultured on CHROMagar Candida medium (CHROMagar, Paris, France) and incubated at 37 C for 48 h for detection of the development of colored colonies (6, 11, 19, 31). Two isolates of C. albicans (ATCC and ATCC 90028) were also included as controls in all experiments. Confirmation of the identities of the presumptively identified C. dubliniensis isolates was done by culturing them on Staib agar (28) containing 50 g of Guizotia abyssinica seed (pulverized),1gofglucose,1gofkh 2 PO 4,1gofcreatinine, and 15 g of agar per liter and incubation at 30 C for 72 h. The appearance of the colonies on the plates was inspected daily both macroscopically and microscopically with a 10 objective (28). Additional confirmation of these isolates as C. dubliniensis was done by substrate assimilation profile analysis with the API 20C AUX yeast identification system (biomerieux), according to the instructions of the manufacturer, with an inoculum derived from 48-h Sabouraud dextrose agar cultures. The results were recorded along with their corresponding codes, and a complete profile number was established for each isolate. Serotyping. As previous studies have shown that C. dubliniensis isolates belong exclusively to C. albicans serotype A (5, 6, 31), all C. dubliniensis isolates were serotyped on the basis of their agglutination reactions with antisera raised against Candida antigenic factors 6 and 13b (Iatron Laboratories, Inc., Tokyo, Japan). Each isolate was freshly subcultured, as specified in the instructions of the manufacturer, and was tested by slide agglutination. C. albicans control strains ATCC (serotype A) and ATCC (serotype B) were also tested (31). Antifungal susceptibility testing. Isolates of C. dubliniensis were tested for their susceptibilities to amphotericin B (E. R. Squibb & Sons Ltd., Hounslow, England), flucytosine (5FC; Sigma), fluconazole (Pfizer Ltd., Sandwich, England), and ketoconazole and itraconazole (Janssen Pharmaceutica, Beerse, Belgium). Broth macrodilution testing was performed according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) (18) with RPMI 1640 medium buffered to ph 7.0 with M morpholinopropanesulfonic acid (MOPS) buffer. The stock drug solutions used for determination of MICs were made in either sterile distilled water or dimethyl sulfoxide, and 0.1 ml was inoculated into each tube. The yeasts at final concentrations of to cells per ml (by use of McFarland turbidity standards) were incubated in air at 35 C for 48 h with twofold dilutions of amphotericin B (0.03 to 16 g/ml), fluconazole (0.125 to 64 g/ml), ketoconazole (0.03 to 16 g/ml), itraconazole (0.03 to 16 g/ml), or 5FC (0.125 to 64 g/ml). The MIC breakpoints were recorded at 24 and 48 h and were interpreted according to the suggestions of an NCCLS subcommittee (18) specifically for C. albicans and those of Rex et al. (25). The MICs of amphotericin B and 5FC for the strains were defined as the lowest concentration of drug that completely (100%) inhibited growth with a score of 0, whereas the MICs of the azoles were the lowest concentrations of the drug that produced an 80% reduction in turbidity with a score of 1 in comparison to the growth for the drug-free control. In view of the unusually high rate of resistance to 5FC observed by the broth macrodilution method, further testing was done by the Etest (AB Biodisk, Solna, Sweden). The Etest is based on the use of a plastic strip impregnated with a concentration gradient of the appropriate drug. Strips containing 5FC ranging in concentration from to 32 g/ml were placed on the surfaces of agar plates containing RPMI 1640 medium, MOPS, and 2% glucose. A pure colony of the test organism was inoculated into sterile distilled water to achieve a turbidity equivalent to that of a 0.5 McFarland standard. The agar plates were inoculated by use of a nontoxic cotton swab. The moisture was allowed to dry for 10 min, and the Etest strips were placed onto the agar surface. The plates were incubated at 35 C for 24 h or until sufficient growth was obtained to determine the endpoint. The results were read and interpreted according to the guidelines of the manufacturer. The MIC was defined as the lowest concentration of antifungal agent (5FC) at which there was 100% inhibition of organism growth. Quality control was ensured for both methods by including quality control strain C. albicans ATCC 90028, as recommended by NCCLS. The interpretive criteria (MICs) used to consider an isolate drug sensitive were as follows: for fluconazole, 64 g/ml; for itraconazole, 1.0 g/ml; for ketoconazole, 1.0 g/ml; for amphotericin B, 1.0 g/ml; and for 5FC, 8.0 g/ml. These were based on studies with C. albicans published previously (18, 24, 25). RESULTS Among the clinical specimens, 32 of the 823 germ tube- and chlamydospore-positive yeast isolates which failed to grow at 45 C were presumptively identified as C. dubliniensis. On the bases of further phenotypic tests, 27 of the 32 isolates (84.4%) recovered from 23 HIV-negative patients were confirmed to be TABLE 1. Frequency of C. dubliniensis isolates among yeasts identified as C. albicans recovered from various clinical specimens No. (%) of yeasts Clinical specimen Total a C. albicans C. dubliniensis High vaginal swab (98.1) 8 (1.9) Urine (96.2) 8 (3.8) Skin (97.3) 2 (2.7) Sputum (97.3) 1 (2.5) Tracheal aspirate (95.8) 1 (4.2) Bronchoalveolar lavage 9 6 (66.7) 3 (33.3) Oral 6 5 (83.3) 1 (16.7) Throat swab 4 4 (100) 0 Blood (83.3) 2 (16.7) Foley catheter tip 6 6 (100) 0 Body fluid (ascitic fluid bile) 5 5 (100) 0 Feces 2 1 (50) 1 (50) Total (96.7) 27 (3.3) a Not included here are the 33 yeasts obtained from preserved stock blood culture isolates, of which 5 were found to be C. dubliniensis (see text for detail). C. dubliniensis, whereas the remaining 5 isolates were confirmed to be C. albicans. Of the 33 blood culture stock isolates, 5 isolates recovered from HIV-negative patients were identified as C. dubliniensis. The prevalence of C. dubliniensis in clinical specimens is shown in Table 1. The majority of isolates were recovered from bronchoalveolar lavage specimens (33.3%), followed by blood specimens (16.7%), oral specimens (16.7%), and other specimens (tracheal aspirate, stool, urine, skin, and high vaginal swabs) (Table 1). Details about the 32 C. dubliniensis isolates (27 isolates recovered from 23 patients and 5 isolates recovered from stock blood cultures) are presented in Table 2. All 32 isolates which failed to grow at 45 C formed short hyphae and chlamydospores in triplets and contiguous pairs considered typical for C. dubliniensis on cornmeal agar and similar to those reported for C. dubliniensis by Sullivan et al. (31). However, both C. albicans ATCC and ATCC showed single terminal chlamydospores regarded as typical of C. albicans. Characteristic dark green-blue colonies were formed by all 32 isolates on CHROMagar Candida medium, suggestive of C. dubliniensis (6, 29, 31), whereas C. albicans control isolates ATCC and ATCC formed lighter green colonies on this medium, typical of C. albicans. Further confirmation of these isolates as C. dubliniensis was based on their formation of rough colonies with abundant hyphae and chlamydospores on Staib agar (28). However, the control C. albicans isolates formed smooth colonies without hyphae and chlamydospores. None of the 32 isolates assimilated xylose or -methyl-d-glucoside, giving the Analytab Products (API) system profiles corresponding to the identification of C. dubliniensis (Table 2). On the other hand, the C. albicans control strains assimilated the two sugars, thus giving the API system code corresponding to the identification of C. albicans. Positive agglutination reactions with antiserum against factor 6 but not with antiserum against factor 13b were observed for all isolates (n 32), and they were therefore grouped as serotype A. Five isolates which did not grow at 45 C and which were considered suspicious proved to be C. albicans on further phe-
3 VOL. 41, 2003 CANDIDA DUBLINIENSIS AT A UNIVERSITY HOSPITAL 1909 TABLE 2. Clinical data and characteristics for C. dubliniensis recovered from clinical specimens a Isolate group and serial no. Age (yr)/sex Clinical condition Specimen APT 20C AUX system assimilation profile code MIC ( g/ml) at 48 h 5FC FLU ITR KET AMB Clinical isolates 1 31/F CBD obstruction Urine , 3 16/F b Laprotomy Abdominal wound 4 45/M UTI Urine /M Lung abscess BAL /F UTI Urine /M Submandibular infection Oral /F Vaginal discharge HVS /F Vaginal discharge HVS /M Urinary incontinence Feces diarrhea 11 33/F Vaginal discharge HVS , 13 31/F b Vaginal discharge HVS /F Vaginal discharge HVS /F Vaginal discharge HVS /F UTI Urine , 18 70/M b Hepatocellular carcinoma Blood /F UTI Urine /F Sleep apnea respiratory Sputum infection 21 36/F Pregnancy Urine , 23 27/F b UTI Urine /M Pneumonia Tracheal aspirate /F Pleural effusion BAL /F Vaginal discharge HVS /F Pneumonia BAL Stock isolates recovered from blood cultures 28 35/F Hepatosplenomegaly Blood ARF 29 40/F Chronic renal failure Blood SLE 30 12/M ALL, fever Blood /M ALL, fever Blood /F Disseminated TB Blood a Abbreviations: F, female; M, male; CBD, chronic bile duct; UTI, urinary tract infection; ARF, acute renal failure; ALL, Acute lymphocytic leukemia; BAL bronchoalveolar lavage; HVS, high vaginal swab; SLE, systemic lupus erythematosus; TB, tuberculosis; FLU, fluconazole; ITR, itraconazole; KET, ketoconazole; AMB, amphotericin B. b Patients from whom C. dubliniensis was recovered from the same specimen on two occasions. notypic tests. These isolates and the control C. albicans isolates formed long hyphae and produced the single terminal chlamydospores regarded as typical of C. albicans on cornmeal agar, formed the light green colonies on CHROMagar Candida medium considered typical for C. albicans, and formed smooth colonies that were similar to those of C. albicans on Staib agar and that on microscopic examination revealed the absence of hyphae, pseudohyphae, and chlamydospores. Positive assimilation of D-xylose and -methyl-d-glucoside was recorded by using the API 20C AUX system and gave the API system code typical of C. albicans, thus confirming their identification. Antifungal susceptibility testing. Testing of the in vitro susceptibilities of the 32 isolates of C. dubliniensis revealed that the MICs of amphotericin B were within the range of to 0.5 g/ml. Ninety-seven percent of the C. dubliniensis isolates were susceptible to each of fluconazole (MIC range, to 4.0 g/ml) and ketoconazole (MIC range, 0.03 to 0.5 g/ml), 87.5% were susceptible to itraconazole (MIC range, 0.03 to 0.5 g/ml), but only 34.4% were susceptible to 5FC (MIC g/ml) (Table 2). One isolate recovered from a high vaginal swab was resistant to three antifungals, fluconazole, ketoconazole, and itraconazole. The MICs of 5FC obtained by the Etest indicated that 65.6% of the C. dubliniensis isolates were resistant to 5FC, as no growth inhibition around the strip was observed (MIC 32 g/ml); however, 11 of 32 (34.4%) isolates showed growth inhibition around the strip below drug concentrations of and g/ml, indicating the susceptibilities of these isolates to 5FC. DISCUSSION This is the first study highlighting the recovery of C. dubliniensis from different clinical specimens from Saudi Arabia. An
4 1910 FOTEDAR AND AL HEDAITHY J. CLIN. MICROBIOL. inability to grow at 45 C was used as an initial screening method for the presumptive identification of C. dubliniensis among isolates previously identified as C. albicans. This is in agreement with the findings of other investigators, who have confirmed that no C. dubliniensis isolate grows at 45 C and that this test can be used to screen large numbers of germ tube- and chlamydospore-positive yeast isolates (11, 12, 22, 23). Several investigators have reported that determination of the inability of C. dubliniensis to grow at 45 C is a reliable test that can be used to differentiate it from C. albicans (9, 11, 12, 22, 23). However, five isolates that did not grow at 45 C failed to give further positive tests for C. dubliniensis and were identified as C. albicans. This indicates that failure to grow at 45 C is not sufficient to confirm the identity of C. dubliniensis (9, 11, 13). In this study, all 32 isolates which produced abundant chlamydospores on cornmeal agar formed dark green colonies on CHROMagar Candida medium and hence were presumptively identified as C. dubliniensis. These results are in agreement with those in reports of several other investigators who have highlighted the use of these tests for the presumptive identification of C. dubliniensis (5, 11, 12, 19, 30, 31). However, since some investigators question the value of these tests (13, 26, 29), we did other confirmatory tests to identify the species, namely, tests for determination of the characteristic morphology on Staib agar medium and sugar assimilation. The use of Staib agar proved useful and was used in one of the confirmatory tests to differentiate C. dubliniensis and C. albicans. Our findings confirm the results of other investigators, indicating the usefulness of Staib agar as a medium for differentiating the two closely related yeast species (2, 28). None of the 32 isolates identified as C. dubliniensis by the methods described above assimilated -methyl-d-glucoside or xylose, the two key sugars used to differentiate C. dubliniensis from C. albicans, indicating the potential of the sugar assimilation test for the differentiation of the two yeast species (9, 12, 21, 23). It has been proposed that the identities of germ tubeand chlamydospore-positive isolates which fail to grow at 45 C can be confirmed by carbohydrate assimilation with the API yeast identification system (11, 12, 21, 23, 31). All the C. dubliniensis isolates tested in this study proved to be serotype A. This finding is in accordance with those of other studies which have shown that C. dubliniensis belongs exclusively to C. albicans serotype A, strongly suggesting that our 32 isolates were C. dubliniensis (6, 23, 29 31). In the present study the recovery of C. dubliniensis from different clinical specimens of HIV-negative patients is highlighted, and our results are in agreement with those presented in earlier reports that described the presence of this novel species among HIV-negative patients (12, 15, 19, 23). The prevalence of C. dubliniensis observed in this study (3.3%) is considerably higher than that reported by Meis et al. (15) among HIV-negative patients (0.8%). However, a higher prevalence (20%) of C. dubliniensis has been reported in the oral cavities of HIV-positive patients (12). In our study a higher prevalence of C. dubliniensis was observed in bronchoalveolar lavage (33.3%) and oral (16.7%) specimens, thereby supporting the earlier findings that C. dubliniensis is an opportunistic pathogen predominately associated with colonization and infection of the oral cavity and upper respiratory tract (6, 12, 15, 23, 27, 29). The recovery of C. dubliniensis from cultures of blood from patients with a variety of clinical conditions indicates that the clinical spectrum of C. dubliniensis is not different from that of C. albicans. Moreover, our results also indicate the ability of C. dubliniensis to cause invasive infection in HIV-negative patients with different clinical conditions, as has been reported earlier (4, 10). To the authors knowledge, the recovery of this yeast from cultures of blood from patients with disseminated tuberculosis and systemic lupus erythematosus has not been reported previously. The amphotericin B MICs for all C. dubliniensis isolates tested in this study were 1 g/ml, which is in agreement with those provided in previous reports (13, 20, 24, 27). Although there is considerable concern about fluconazole resistance among clinical isolates of C. dubliniensis recovered from HIVinfected patients previously treated with the drug (16, 17, 20), we found that a very low percentage of C. dubliniensis isolates were resistant to fluconazole and ketoconazole. These results are in agreement with those of Odds et al. (19) and Pfaller et al. (20); however, Quindos et al. (24) reported significantly higher rates of resistance to fluconazole (17%) and ketoconazole (24%) in the non-hiv-infected patients. Resistance to itraconazole was seen in 12.5% of our isolates, which is almost similar to the 13.8% resistance rate indicated by Quindos et al. (24), whereas low resistance rates (0 and 4.6%) have been reported by other investigators (13, 20). A high percentage (65.6%) of our C. dublinineisis isolates were resistant to 5FC in vitro. This is contrary to the results of other investigators, who did not observe 5FC resistance in C. dubliniensis (19, 20, 24, 27), although McCullough et al. (14) reported that these isolates were less susceptible to 5FC. It is worth mentioning that clinically 5FC is used in combination with other antifungals for the treatment of fungal infections (7). This study constitutes the first report of the isolation of C. dubliniensis from clinical specimens recovered in Saudi Arabia. REFERENCES 1. Al-Hedaithy, S. S. A., and R. Fotedar Recovery and studies on chlamydospore-negative Candida albicans isolated from clinical specimens. Med. Mycol. 40: Al-Mosaid, A., D. Sullivan, I. F. Salkin, D. Shanley, and D. C. Coleman Differentiation of Candida dubliniensis from Candida albicans on Staib agar and caffecic acid-ferric citrate agar. J. Clin. Microbiol. 39: Boyle, B. M., D. J. Sullivan, C. Forkin, F. Mulcahy, C. T. Keane, and D. C. Coleman Candida dubliniensis candidemia in an HIV-positive patients in Ireland. Int. J. Sex. Transm. Dis. AIDS 1: Brandt, M. E., L. H. Harrison, M. Pass, A. N. Sofair, S. Huie, R. K. Li, C. J. Morrison, D. W. Warnock, and R. A. Hajjeh Candida dubliniensis fungemia: the first four cases in North America. Emerg. Infect. Dis. 6: Coleman, D., D. Sullivan, K. Haynes, M. Henman, D. Shanley, D. Bennett, G. Moran, C. McCreary, L. O. Neill, and B. Harrington Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis. 3(Suppl.):S96 S Coleman, D. C., D. J. Sullivan, D. E. Bennett, G. P. Moran, H. J. Barry, and D. B. Shanley Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 11: Cuenca-Estrella, M., T. M. Diaz-Guerra, E. Mellado, and J. L. Rodriguez- Tudela Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur. J. Clin. Microbiol. Infect. Dis. 20: Elie, C. M., T. J. Lott, E. Reiss, and C. J. Morrison Rapid identification of Candida species with species-specific DNA probes. J. Clin. Microbiol. 36: Gales, A. C., M. A. Pfaller, A. K. Houston, S. Joly, D. J. Sullivan, D. C. Coleman, and D. R. Soll Identification of Candida dubliniensis based on temperature and utilization of xylose and -methyl-d-glucoside as determined with the API 20C AUX and Vitek YBC stystems. J. Clin. Microbiol. 37: Gottlieb, G. S., A. P. Limaye, Y. C. Chen, and W. C. Van Voorhis
5 VOL. 41, 2003 CANDIDA DUBLINIENSIS AT A UNIVERSITY HOSPITAL 1911 Candida dubliniensis fungemia in a solid organ transplant patient: case report and review of literature. Med. Mycol. 39: Jabra-Rizk, M. A., A. A. Baqui, J. I. Kelley, W. A. Falker, W. G. Merz, and T. F. Meiller Identification of Candida dubliniensis in a prospective study of patients in the United States. J. Clin. Microbiol. 37: Jabra-Rizk, M. A., W. A. Falkler, Jr., W. G. Merz, A. A. M. A. Baqui, J. I. Kelley, and T. F. Meiller Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-hiv-infected individuals. J. Clin. Microbiol. 38: Kirkpatrick, W. R., S. G. Revankar, R. K. McAtee, J. L. Lopez-Ribot, A. W. Fothergill, D. I. McCarthy, S. E. Sanche, R. A. Cantu, M. G. Rinaldi, and T. F. Patterson Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates. J. Clin. Microbiol. 36: McCullough, M., B. Ross, and P. Reade Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus. J. Clin. Microbiol. 33: Meis, J. F., F. M. Verduyn Lunel, P. E. Verweij, and A. Voss One-year prevalence of Candida dubliniensis in a Dutch university hospital. J. Clin. Microbiol. 38: Moran, G. P., D. J. Sullivan, M. C. Henman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-hiv-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41: Moran, G. P., D. Sanglard, S. M. Donnelly, D. B. Shanley, D. J. Sullivan, and D. C. Coleman Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 42: National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa. 19. Odds, F. C., L. Van Nuffel, and G. Dams Prevalence of Candida dubliniensis isolates in a yeast stock collection. J. Clin. Microbiol. 35: Pfaller, M. A., S. A. Messer, S. Gee, S. Joly, C. Pujol, D. J. Sullivan, D. C. Coleman, and D. R. Soll In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37: Pincus, D. H., D. C. Coleman, W. R. Pruitt, A. A. Padhye, I. F. Salkin, M. Geimer, A. Bassel, D. J. Sullivan, M. Clarke, and V. Hearn Rapid identification of Candida dubliniensis with commercial yeast identification systems. J. Clin. Microbiol. 37: Pinjon, E., D. Sullivan, I. Salkin, D. Shanley, and D. Coleman Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J. Clin. Microbiol. 36: Polacheck, I., J. Strahilevitz, D. Sullivan, S. Donnelly, I. F. Salkin, and D. C. Coleman Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel. J. Clin. Microbiol. 38: Quindos, G., A. J. Carillo-Munoz, M. P. Arevalo, J. Salgado, R. Alonso- Vargas, J. M. Rodrigo, M. T. Ruesga, A. Valverde, J. Peman, E. Canton, E. Martin-Mazuelos, and J. Ponton In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy (Basel) 46: Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry Development of interpretive break points for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24: Schoofs, A., F. C. Odds, R. Colebunders, M. Ieven, and H. Goossens Use of specialized isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. Eur. J. Clin. Infect. Dis. 16: Sebti, A., T. E. Kiehn, D. Perlin, V. Chaturvedi, M. Wong, A. Doney, S. Park, and K. A. Sepkowitz Candida dubliniensis at a cancer center. Clin. Infect. Dis. 32: Staib, P., and J. Morschhauser Chlamydospore formation on Staib agar as a species-specific characteristic of Candida dubliniensis. Mycoses 42: Sullivan, D., and D. Coleman Candida dubliniensis: characteristics and identification. J. Clin. Microbiol. 36: Sullivan, D., K. Haynes, J. Bille, P. Boerlin, L. Rodero, S. Lloyd, M. Henman, and D. Coleman Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J. Clin. Microbiol. 35: Sullivan, D. J., T. J. Westerneng, K. A. Haynes, D. E. Bennett, and D. C. Coleman Candida dubliniensis sp. nov: phenotypic and molecular characterisation of a novel species associated with oral candidosis in HIVinfected individuals. Microbiology 141:
Differentiation of Candida dubliniensis from Candida albicans on Staib Agar and Caffeic Acid-Ferric Citrate Agar
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 323 327 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.323 327.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Differentiation
More informationRecovery of Candida dubliniensis from Non-Human Immunodeficiency Virus-Infected Patients in Israel
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2000, p. 170 174 Vol. 38, No. 1 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Recovery of Candida dubliniensis from
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationCandida dubliniensis Identification in Brazilian Yeast Stock Collection
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 98(4): 533-538, June 2003 533 Candida dubliniensis Identification in Brazilian Yeast Stock Collection Priscilla de Laet Sant Ana Mariano, Eveline Pípolo Milan/*,
More informationAntifungal susceptibility testing using the E test: comparison with the broth macrodilution technique
Journal of Antimicrobial Chemotherapy (996) 7, 65-7 Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique Sharon C. A. Chen, Maryann L. O'Donnell, Suzannah
More informationWidespread Geographic Distribution of Oral Candida dubliniensis Strains in Human Immunodeficiency Virus-Infected Individuals
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1997, p. 960 964 Vol. 35, No. 4 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Widespread Geographic Distribution of Oral Candida dubliniensis
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationSpecies distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002
Fluconazole J Microbiol Immunol susceptibility Infect of Candida 2004;37:236-241 Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002 Jiun-Ling Wang
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationSYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II
SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II DURAN NIZAMI 1, MUZ MUSTAFA 2, DURAN GULAY GULBOL 3, OZER BURCIN 1, ONLEN YUSUF 4 1 Mustafa
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationCandida dubliniensis endophthalmitis: five cases over 15 years
Moloney and Park Journal of Ophthalmic Inflammation and Infection 2013, 3:66 ORIGINAL RESEARCH Open Access Candida dubliniensis endophthalmitis: five cases over 15 years Thomas P Moloney * and Joseph Park
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationOral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina
Original article Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina A. G. Luque, 1 M. S. Biasoli, 1 M. E. Tosello, 1 A. Binolfi, 1 S. Lupo 2 and H. M. Magaró 1 1 CEREMIC,
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article In Vitro Antifungal Susceptibility Pattern of Oropharyngeal and Oesophageal Candida Species
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationon November 3, 2018 by guest
JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1811 1820 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00134-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationSusceptibilities of Candida spp. to Antifungal Agents Visualized by Two-Dimensional Scatterplots of Relative Growth
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1996, p. 588 594 Vol. 40, No. 3 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Susceptibilities of Candida spp. to Antifungal Agents
More informationReduced Azole Susceptibility in Genotype 3 C. dubliniensis Isolates Associated with Increased CdCDR1 and CdCDR2 Expression
1 1 1 1 1 1 1 1 0 1 Reduced Azole Susceptibility in Genotype C. dubliniensis Isolates Associated with Increased CdCDR1 and CdCDR Expression EMMANUELLE PINJON, 1 COLIN J. JACKSON, STEVEN L. KELLY, DOMINIQUE
More informationANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2000, p Vol. 44, No. 8
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2000, p. 2081 2085 Vol. 44, No. 8 0066-4804/00/$04.00 0 Quantitation of Candida albicans Ergosterol Content Improves the Correlation between In Vitro Antifungal
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Shrutika Wandre et al. Special Issue, 2015, pp. 25-36 PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI Shrutika Wandre Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing,
More informationReceived 7 March 2002/Returned for modification 16 April 2002/Accepted 13 June 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2002, p. 3204 3208 Vol. 40, No. 9 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.9.3204 3208.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationPotato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1455 1461 Vol. 46, No. 5 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.5.1455 1461.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationQuantitation of Ergosterol Content: Novel Method for Determination of Fluconazole Susceptibility of Candida albicans
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1999, p. 3332 3337 Vol. 37, No. 10 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Quantitation of Ergosterol Content:
More informationPREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI
Wandre et al., 2015 Volume 1 Issue 1, pp. 25-36 Year of Publication: 2015 DOI- https://dx.doi.org/10.20319/lijshls.2015.s11.2536 This paper can be cited as: Wandre, S., Sanap, S., Mukadam, T., Vaidya,
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationSusceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin B
OnLine Journal of Biological Sciences 10 (2): 109-113, 2010 ISSN 1608-4217 2010 Science Publications Susceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationIdentification of Yeasts. Medical Mycology Training Network 15 November 2018 Dr Tan Ai Ling Department of Microbiology, Singapore General Hospital
Identification of Yeasts Medical Mycology Training Network 15 November 2018 Dr Tan Ai Ling Department of Microbiology, Singapore General Hospital Definition of Yeasts Eukaryote cells have defined nucleus
More informationOpportunistic Mycoses
CANDIDIASIS SOFYAN LUBIS DEPARTEMEN MIKROBIOLOGI FAK.KEDOKTERAN USU MEDAN 2009 Opportunistic Mycoses Opportunistic mycoses are fungal infections that do not normally cause disease in healthy people, but
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationReceived 15 October 2001/Returned for modification 27 May 2002/Accepted 24 June 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2002, p. 3268 3272 Vol. 46, No. 10 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.10.3268 3272.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationReceived 24 September 2001/Returned for modification 2 February 2002/Accepted 31 May 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2002, p. 2982 2989 Vol. 46, No. 9 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.9.2982 2989.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationInt.J.Curr.Microbiol.App.Sci (2014) 3(10)
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 816-822 http://www.ijcmas.com Original Research Article Identification and In vitro Azole resistance of Candida species isolated from Oropharyngeal Candidiasis
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationCHARACTERIZATION AND SUSCEPTIBILITY PATTERN OF CANDIDA ISOLATES FROM HIV - SEROPOSITIVE PATIENTS IN A TERTIARY CARE HOSPITAL
CHARACTERIZATION AND SUSCEPTIBILITY PATTERN OF CANDIDA ISOLATES FROM HIV - SEROPOSITIVE PATIENTS IN A TERTIARY CARE HOSPITAL Apurba Sankar Sastry, Sandhya Bhat K, Anand Sankar Sastry, Kumudavathi M S,
More informationInterlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2004, p. 3475 3482 Vol. 42, No. 8 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.8.3475 3482.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationCan the diagnosis of recurrent vulvovaginal candidosis be improved by use of vaginal lavage samples and cultures on chromogenic agar?
Can the diagnosis of recurrent vulvovaginal candidosis be improved by use of vaginal lavage samples and cultures on chromogenic agar? Novikova, N; Rodrigues, A; Mårdh, Per-Anders Published in: Infectious
More informationRapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2010, p. 2205 2212 Vol. 48, No. 6 0095-1137/10/$12.00 doi:10.1128/jcm.02321-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Rapid Antifungal
More informationThe Effect of Dimethyl Sulfoxide DMSO on the Growth of Dermatophytes
Jpn. J. Med. Mycol. Vol. 47, 313 318, 2006 ISSN 0916 4804 Original Article The Effect of Dimethyl Sulfoxide DMSO on the Growth of Dermatophytes Muhammad Akram Randhawa Department of Pharmacology, College
More informationRapid Species Identification and Antifungal Susceptibility Testing of Candida Isolated from Different Hospital Acquired Infections by VITEK 2 System
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 764-772 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.090
More informationUse of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species
Brazilian Journal of Microbiology 44, 4, 1257-1266 (2013) ISSN 1678-4405 Copyright 2013, Sociedade Brasileira de Microbiologia www.sbmicrobiologia.org.br Research Paper Use of the VITEK 2 system to identify
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationRapid Identification and Antifungal Susceptibility Pattern of Candida Isolates from Critically Ill Patients with Candiduria
Original Article Vol. 26 No. 2 Rapid identification and antifungal susceptibility pattern of Candida isolates:- Chaudhary U, et al. 49 Rapid Identification and Antifungal Susceptibility Pattern of Candida
More informationPathogens with Intermediate Virulence Dermatophytes opportunistic Pathogens
Pathogens with Intermediate Virulence Dermatophytes opportunistic Pathogens Cryptococcus neoformans Candida albicans Aspergillus species Pneumocystis carinii 1 Dermatophytes Named for derma skin Cause
More informationSusceptibility of Candida dubliniensis to Salivary Histatin 3
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2003, p. 70 76 Vol. 47, No. 1 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.1.70 76.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationReceived 5 August 2004/Accepted 26 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 512 517 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.512 517.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationReceived 1 December 2009/Accepted 26 January 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2010, p. 1541 1546 Vol. 54, No. 4 0066-4804/10/$12.00 doi:10.1128/aac.01688-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Evaluation
More informationSpeciation of Candida Isolated from Various Clinical Samples and their Antifungal Susceptibility Profile in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 7 (2016) pp. 54-60 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.507.004
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationIntroduction. Study of fungi called mycology.
Fungi Introduction Study of fungi called mycology. Some fungi are beneficial: ex a) Important in production of some foods, ex: cheeses, bread. b) Important in production of some antibiotics, ex: penicillin
More informationDownloaded from Candiduria In Immunocompromised Individuals In A Tertiary Care Center In Northern India
Submitted on: March 2015 Accepted on: March 2015 For Correspondence Email ID: Medrech ISSN No. 2394-3971 Research Article CANDIDURIA IN IMMUNOCOMPROMISED INDIVIDUALS IN A TERTIARY CARE CENTER IN NORTHERN
More informationMultilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1543 1548 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01510-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multilaboratory
More informationmycoses Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya Summary Introduction
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya Rennatus Mdodo,
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationDistribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999
Diagnostic Microbiology and Infectious Disease 48 (2004) 33 37 Mycology Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999 Ming-Fang Cheng a,b,c,e, Kwok-Woon
More informationClinical and microbiological assessment of patients with a long-term diagnosis of human immunodeficiency virus infection and Candida oral colonization
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02707.x Clinical and microbiological assessment of patients with a long-term diagnosis of human immunodeficiency virus infection and Candida oral colonization
More informationIN-VITRO SENSITIVITY OF AMPHOTERICIN B, ITRACONAZOLE AND FLUCONAZOLE - RESISTANT AGAINST CANDIDA ALBICANS
IJPSR (2011), Vol. 2, Issue 11 (Research Article) Received on 03 July, 2011; received in revised form 17 September, 2011; accepted 29 October, 2011 IN-VITRO SENSITIVITY OF AMPHOTERICIN B, ITRACONAZOLE
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationdida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans
dida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans Key words: Susceptibility test, IC99, miconazole, fluconazole, itraconazole, Micro-dilution method, 96-multiwell plate Table 1. Cunteffis
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationAntifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients
ISSN: 2319-7706 Volume 4 Number 3 (2015) pp. 716-720 http://www.ijcmas.com Original Research Article Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients Deepak Kumar 1, Sayan
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationon December 9, 2018 by guest
JCM Accepts, published online ahead of print on 27 June 2012 J. Clin. Microbiol. doi:10.1128/jcm.00937-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Progress in Antifungal
More informationFluconazole Susceptibility Profile of Candida isolates Recovered from Patients Specimens Admitted to Yazd Central Laboratory
Iranian Journal of Pharmaceutical Research (2008), 7 (1): 69-75 Received: June 2007 Accepted: November 2007 Copyright 2008 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health
More informationReceived 12 May 2010/Returned for modification 24 June 2010/Accepted 6 July 2010
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2010, p. 3153 3157 Vol. 48, No. 9 0095-1137/10/$12.00 doi:10.1128/jcm.00952-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More information2046: Fungal Infection Pre-Infusion Data
2046: Fungal Infection Pre-Infusion Data Fungal infections are significant opportunistic infections affecting transplant patients. Because these infections are quite serious, it is important to collect
More informationOral colonization of Candida species in perinatally HIV-infected children in northern Thailand
101 Journal of Oral Science, Vol. 46, No. 2, 101-105, 2004 Original Oral colonization of Candida species in perinatally HIV-infected children in northern Thailand Surawut Pongsiriwet, Anak Iamaroon,Pojana
More informationAntifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-aids patients in Southeast China
BRAZ J INFECT DIS. 2012;16(2):175-179 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Brief Communication Antifungal susceptibilities of Cryptococcus species complex isolates
More informationReceived 27 May 2004/Returned for modification 11 July 2004/Accepted 16 December 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2005, p. 1364 1368 Vol. 49, No. 4 0066-4804/05/$08.00 0 doi:10.1128/aac.49.4.1364 1368.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationSpeciation and susceptibility testing of Candida isolates from vaginal discharge
Speciation and susceptibility testing of Candida isolates from vaginal discharge Swapna Muthusamy 1 and Selvi Elangovan 2 1. Sri Venkateshwaraa Medical College Hospital and Research Centre, Puducherry,
More informationTOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018
TOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018 MCE01 Conflict of interest disclosure In the past 5 years, M.C.E. has received grant support from Astellas Pharma,
More informationInducible Azole Resistance Associated with a Heterogeneous Phenotype in Candida albicans
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2001, p. 52 59 Vol. 45, No. 1 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.1.52 59.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationIn Vitro Studies with R 51,211 (Itraconazole)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1984, p. 5-9 Vol. 26, No. 1 0066-4804/84/070005-05$02.00/0 Copyright 1984, American Society for Microbiology In Vitro Studies with R 51,211 (Itraconazole) ANA
More informationOriginal Article Characterization of candida species isolated from cases of lower respiratory tract infection
Kathmandu University Medical Journal (2006), Vol. 4, No. 3, Issue 15, 290-294 Original Article Characterization of candida species isolated from cases of lower respiratory tract infection Jha BK 1, Dey
More informationThe antifungal susceptibilities of oral Candida spp isolates from HIV-infected patients
Advanced Journal of Microbiology Research Volume 2015 Available online at http://advancedresearchjournals.org/ajmr Advanced Research Journals Full Length Research Paper The antifungal susceptibilities
More informationIn vitro antifungal susceptibility of Scopulariopsis brevicaulis isolates
Medical Mycology, 2014, 52, 723 727 doi: 10.1093/mmy/myu039 Advance Access Publication Date: 21 July 2014 Original Article Original Article In vitro antifungal susceptibility of Scopulariopsis brevicaulis
More informationAvailable online at journal homepage:
Kaohsiung Journal of Medical Sciences (2012) 28, 306e315 Available online at www.sciencedirect.com journal homepage: http://www.kjms-online.com ORIGINAL ARTICLE Fluconazole exposure rather than clonal
More informationEVALUATION OF ETEST AND MACRODILUTION BROTH METHOD FOR ANTIFUNGAL SUSCEPTIBILITY TESTING OF
Rev. Inst. Med. trop. S. Paulo 44 (3):121-125, May-June, 2002. EVALUATION OF ETEST AND MACRODILUTION BROTH METHOD FOR ANTIFUNGAL SUSCEPTIBILITY TESTING OF Candida sp STRAINS ISOLATED FROM ORAL CAVITIES
More informationTriazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2006, p. 529 535 Vol. 44, No. 2 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.2.529 535.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Triazole
More information